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1.1 Types of toxin-based model Due	to	the	diversity	in	the	range	of	toxins	used	to	cause	demyelination	and	their	modes	of	delivery,	this	chapter	will	focus	on	three	of	the	most	common	models.	Focal	injection	of	two	substances	(lysolecithin	and	ethidium	bromide)	will	be	discussed,	as	will	administration	of	cuprizone	in	the	diet.	Other	toxins	reported	to	cause	primary	demyelination	in	animal	models	include	6-aminonicotinamide	[2],	antibodies	to	myelin	proteins	(e.g.	[3])	and	bacterial	endotoxin	[4],	and	these	are	briefly	summarised	in	Table	1.		
Table	1:	Overview	of	toxin-based	models	for	demyelination/remyelination.	
Toxin Focal / Systemic Mechanism Principal uses 
Lysolecithin Focal	 • Detergent	effect	on	oligodendrocytes	
• Activates	immune	cells	 • Most	commonly	used	focal	model,	with	very	well-defined	kinetics	
• Electrophysiological	recordings	in	a	specific	location		
Ethidium Bromide Focal	 • Intercalates	in	DNA	
• Affects	all	nuclei	in	lesion,	sparing	axons	 • Remyelination	in	the	relative	absence	of	astrocytes	• Lesions	in	CCP	can	be	combined	with	an	in-dwelling	catheter	for	infusion	
































































































3.1 PROTOCOL: Lysolecithin lesion in mouse ventral spinal cord Spinal	cord	lesions	are	normally	carried	out	on	mice	aged	8	weeks	and	onwards.	The	procedure	should	take	less	than	30	minutes	and	sterile	saline	can	be	applied	periodically	to	prevent	the	wound	from	drying	out.		 1. Prepare	anaesthetic	machine,	operating	microscope,	operating	table	with	stage	suitable	for	mice,	and	sterile	surgical	instruments.			2. Prepare	the	following	syringes:	
• Glass-tipped	Hamilton	syringe	with	1%	lysolecithin	-	ensure	there	are	no	bubbles	and	attach	this	to	a	3-way	manipulator	fitted	to	a	stand	
• 1	ml	syringe	of	analgaesic	e.g.	buprenorphine,	0.05	mg/kg.		3. Weigh	mouse	and	transfer	to	anaesthetic	chamber	to	begin	induction	of	anaesthesia	with	isoflurane/oxygen.	When	effective,	transfer	mouse	to	operating	stage	equipped	with	mask	for	maintaining	anaesthesia	throughout	the	procedure.	Position	mouse	prone	with	head	away	from	operator.		4. Inject	analgaesic	subcutaneously.	Position	the	temperature	probe	and	apply	1	drop	of	Viscotears	liquid	gel	to	each	eye.		5. Prepare	skin	by	shaving	the	back	around	the	natural	“hump”	and	clean	the	shaved	area	with	antiseptic	solution.	Do	not	treat	excessively	to	prevent	heat	loss.	Cut	a	small	access	window	in	a	sterile	drape	and	lay	over	mouse.		6. Begin	operating	after	verifying	the	mouse	has	no	response	to	pain.	Start	with	a	0.5	cm	midline	incision	at	the	top	of	the	hump	on	the	back	(thoraco-lumbar	region).	Cut	away	the	subcutaneous	tissue	to	expose	the	muscles.	Use	a	small	scalpel	blade	to	gently	separate	the	muscles	on	both	sides.		7. Under	the	microscope,	find	the	space	between	two	vertebrae	using	two	pairs	of	fine-tipped	tweezers	and	remove	the	soft	tissues:	first	muscle	and	then	the	yellow	ligament	to	expose	the	surface	of	the	spinal	cord.	This	should	appear	pale	with	the	central	vein	visible	in	the	midline.	Care	must	be	taken	not	to	damage	the	spinal	cord	at	this	stage.		8. Use	a	pair	of	curved	mosquito	forceps	to	clamp	the	soft	tissue	above	the	exposed	intervertebral	space,	then	fix	to	a	stand	to	minimise	movement	of	the	injection	site	from	breathing.	Use	a	very	thin	bevelled	needle	(such	as	a	30G	dental	needle)	to	open	the	dura	just	to	the	right	of	the	central	vein	(Fig	3).		
9. Position	the	manipulator	with	the	Hamilton	syringe	at	a	70°	angle	relative	to	the	horizontal	plane.	Gentle	adjust	the	tip	of	the	syringe	to	touch	the	surface	of	the	cord	through	the	cut	dura.	Slowly	lower	the	needle	through	the	cord,	until	a	slight	deflection	indicates	contact	with	the	vertebral	bone	underneath.	Retract	the	needle	fractionally	so	the	deflected	tip	becomes	straight.		10. Inject	0.5	μl	of	toxin	in	about	20	seconds,	then	retract	the	needle	about	0.2-0.25	mm	and	inject	another	0.5	μl.	Keep	the	needle	in	place	for	1	minute.		11. Slowly	raise	the	needle	out	of	the	spinal	cord.	And	move	away	clamp	and	manipulator.	Using	a	6-0	suture,	make	one	stitch	to	close	the	muscular	layer,	then	2-3	stitches	for	the	skin.	Lidocaine	cream	can	be	applied	to	reduce	pain	at	the	wound	site.		12. Transfer	the	mouse	to	a	warm	chamber	for	recovery	before	returning	it	to	the	cage.			After	the	procedure,	there	should	be	no	signs	of	distress	or	clinical	abnormality.	No	special	care	is	required	and	individual	cages	are	not	necessary.	Occasionally	a	mouse	may	develop	a	unilateral	hind	leg	impairment,	which	should	recover	in	within	48	hours	and	will	not	prevent	animal	accessing	food	or	water.	External	sutures	are	often	removed	by	the	mouse,	and	may	need	to	be	replaced	if	this	occurs	before	wound	closure.		
3.2 PROTOCOL: Ethidium bromide lesion in rat caudal cerebellar peduncle Lesions	of	the	CCP	are	typically	carried	out	on	rats	aged	8	weeks	and	onwards.	The	procedure	is	more	complex	than	spinal	cord	lesions	due	to	the	need	to	drill	through	the	skull	and	use	precise	stereotactic	coordinates.	In	total,	it	should	take	around	45-60	minutes.		 1. Prepare	anaesthetic	machine,	operating	microscope,	operating	table	with	stereotactic	frame,	and	sterile	surgical	instruments.		2. Prepare	the	following	syringes:	
• Hamilton	syringe	(with	26G	needle)	with	0.01%	ethidium	bromide	-	ensure	there	are	no	bubbles	and	attach	this	to	stereotactic	frame	
• 5	ml	syringe	of	sterile	saline	-	place	in	recovery	unit	to	warm	
• 1	ml	syringe	of	analgaesic	e.g.	buprenorphine,	0.05	mg/kg.		3. Weigh	rat	and	transfer	to	anaesthetic	chamber	to	begin	induction	of	anaesthesia	with	isoflurane/oxygen.	When	effective,	inject	analgaesic	(subcutaneous)	and	2.5-3	ml	saline	(intraperitoneal).	Position	the	temperature	probe.		4. Shave	top	of	head	from	between	the	eyes	to	behind	the	ears.	Scrub	area	with	two	gauze	swabs	wetted	with	antiseptic	solution	and	apply	1	drop	of	
Viscotears	liquid	gel	to	each	eye.		5. Transfer	rat	to	stereotactic	frame	equipped	with	mask	for	maintaining	anaesthesia	throughout	the	procedure.	Open	the	mouth	and	pull	tongue	outside	if	possible.	Attach	the	ear	bars	carefully,	holding	the	animal.	Each	bar	should	be	in	the	same	position	and	an	eye-closing	reflex	can	be	seen	when	the	bar	is	correctly	located.	The	head	of	the	animal	should	be	positioned	flat,	which	can	be	verified	once	the	skull	is	exposed.		6. Apply	skin	prep	to	the	shaved	area	skin.	Cut	a	small	access	window	in	a	sterile	drape	and	lay	over	rat.		7. Using	a	scalpel,	make	a	1.5	cm	midline	incision	at	the	back	of	the	head.	Remove	the	connective	tissue	with	scissors	and	forceps.	Cotton	wool	can	be	used	to	stop	the	bleeding.	Scrape	away	tissue	overlying	the	bone	with	the	scalpel.		8. With	the	aid	of	the	microscope,	locate	the	bregma	and	note	its	coordinates,	β	(Fig	4).	Touching	the	bones	to	move	them	slightly	can	aid	with	this.		9. Locate	the	lambda,	which	is	defined	as	the	midpoint	of	the	curve	of	best	fit	along	the	lambda	suture	(Fig	4)	rather	than	the	intersection	of	the	lambdoid	and	sagittal	sutures	[73].	Note	its	coordinates,	λ.		10. Confirm	that	β	and	λ	lie	on	the	same	horizontal	plane,	and	adjust	the	position	of	the	rat	as	necessary.		11. Calculate	the	stereotactic	coordinates	for	the	CCP	using	Table	2.	These	will	depend	on	the	size	of	the	rat,	and	thus	the	β-λ	distance.	
	
Table	2:	Guide	for	calculating	the	coordinates	of	CCP	relative	to	lambda,	λ		
12. Apply	the	retractor.	Position	tip	of	drill	at	the	point	of	entry.		13. Drill	through	the	skull,	advancing	slowly.	The	syringe	can	be	used	periodically	to	confirm	the	hole	is	in	the	correct	location.		14. When	drilling	is	complete,	move	the	syringe	to	the	calculated	coordinates	for	the	CCP.	The	coordinates	can	be	adjusted	slightly	if	the	needle	catches	on	the	edge	of	the	burr	hole.	This	is	preferable	to	allowing	the	needle	to	deflect,	which	may	result	in	the	tip	being	several	millimetres	away	from	the	intended	site.		
 Β-λ (mm) <8.0 8.0 - 8.2 8.2 - 8.5 8.5 - 9.0 9.0 - 9.5 >9.5 
Distance to 
CCP (mm) 
Anterior 2.1	 2.2	 2.2	 2.2	 2.3	 2.4	
Ventral 7.1	-	7.2	 7.2	 7.2	 7.2	 7.3	 7.4	
Lateral 2.5	 2.5	 2.5	 2.5	 2.6	 2.65	
15. Inject	4	μl	in	4	minutes,	then	wait	another	4	minutes.	Remove	the	syringe	slowly,	and	stop	any	bleeding.		16. Remove	the	retractor	and	close	the	skin	with	5-0	suture.		17. Transfer	the	rat	to	a	warm	chamber	for	recovery	before	returning	it	to	the	cage.			The	surgery	for	CCP	lesions	involves	more	risk	than	for	spinal	cord	lesions	(e.g.	haemorrhage)	and	post-operative	complications	are	also	more	common.	For	the	first	24	hours	after	the	procedure,	the	rat	should	be	housed	individually	and	provided	with	a	liquid/gel	diet	ad	libitum	and	a	long	spout	water	bottle.	If	showing	signs	of	pain,	another	dose	of	analgaesic	can	be	administered	several	hours	after	surgery.	Rats	are	often	lethargic	following	the	surgery	but	should	regain	their	usual	level	of	activity	over	2-3	days.	If	a	mild	head	tilt	develops	post-operatively,	this	should	be	monitored,	with	special	feeding	arrangements	as	required,	and	will	usually	resolve.	In	occasional	cases,	a	rat	may	develop	spontaneous	rolling	and	will	need	to	be	culled.	
3.3 PROTOCOL: Dietary administration of cuprizone to mice The	effects	of	cuprizone	can	depend	on	the	species,	strain,	age	and	gender	of	the	animals	used.	The	literature	standard	is	to	use	8-week	old	male	C57BL/6	mice,	and	feed	a	diet	of	0.2%	cuprizone	for	4-6	weeks	[52].		 1. For	a	period	of	4-6	weeks,	substitute	the	regular	feed	with	a	0.2%	cuprizone	diet.	This	should	be	replaced	every	2-3	days,	due	to	degradation	of	the	toxin.	Food	intake	can	be	estimated	as	4-5g	per	mouse	per	day.		2. Cuprizone	poses	a	safety	risk	through	skin	contact	or	inhalation.	For	this	reason,	mice	should	be	housed	in	sealed	cages	and	diet/bedding	changes	carried	out	in	a	biological	safety	cabinet	with	appropriate	waste	disposal.		3. Mouse	weights	should	be	monitored	throughout	the	experiment.	Weight	loss	often	occurs	during	the	first	1-2	weeks	of	administration,	with	subsequent	weight	gain.		4. Mice	are	often	returned	to	their	regular	diet	for	1-2	weeks	for	a	period	of	remyelination	without	ongoing	demyelination.		Under	these	conditions,	substantial	demyelination	is	achieved	whilst	minimising	clinical	severity,	which	is	frequent	at	higher	doses	[46,	74].	However,	some	weight	loss	is	common	and	other	signs	have	been	reported	including	reduced	social	interaction	[75]	and	impaired	performance	on	a	balance-beam	task	[76].				 	
4. Notes 
4.1 Identifying Remyelination Several	methods	can	be	used	to	visualise	and	quantify	myelin,	including	immunohistochemistry	for	myelin	protein,	light	microscopy	dyes	including	luxol	fast	blue	or	lipophilic	fluorophores	such	as	FluroMyelin	(ThermoFisher).	Magnetic	resonance	imaging	(MRI)	can	also	be	useful	tool	to	map	myelin	across	the	entire	brain.	However,	these	techniques	are	unable	to	distinguish	between	the	myelin	produced	during	remyelination	and	that	originating	in	development.	Thus,	it	can	be	difficult	to	determine	whether	an	intervention	has	truly	enhanced	remyelination,	or	if	more	of	the	original	sheaths	have	survived.		At	a	higher	resolution	it	becomes	clear	that	the	dimensions	of	the	myelin	relative	to	its	axon	differs	between	myelination	and	remyelination.	During	development,	myelin	sheath	thickness	increases	with	larger	diameter	axons.	In	remyelination,	this	relationship	is	not	maintained	and	thus	a	given	diameter	axon	will	be	myelinated	by	a	sheath	which	appears	thinner	and	with	shorter	internodes	than	developmentally	generated	myelin	(Fig	5)	[77].	To	be	able	to	visualise	this,	the	ultrastructure	of	the	tissue	must	be	very	well	preserved,	and	this	is	best	done	by	perfusion-fixing	animals	in	gluteraldehyde	before	embedding	regions	of	interest	resin	[78].	Myelin	sheath	thickness	can	then	be	measured	using	1	μm	sections	stained	with	toluidine	blue	(with	practice),	or	using	electron	microscopy.	The	thinner	sheaths	are	less	clear	in	regions	of	the	CNS	with	smaller-diameter	axons	such	as	the	corpus	callosum,	which	can	be	problematic	for	interpreting	electron	microscopy	in	the	cuprizone	model	[74].	
4.2 Other outcome measures for toxin-based models Besides	imaging	myelin	sheaths	themselves	a	wide	variety	of	techniques	have	been	applied	to	toxin-induced	lesions	to	study	the	cells	and	molecular	cues	involved	in	demyelination	and	remyelination.	To	preserve	the	CNS	for	immunohistochemistry,	a	perfusion-fixation	method	using	4%	paraformaldehyde	in	PBS	is	recommended.	This	delivers	fixative	rapidly	and	uniformly	to	all	tissues,	and	is	thus	preferable	to	immersion-fixation	[79].	In	situ	hybridisation	is	a	useful	alternative	to	immunohistochemistry,	particularly	to	visualise	transcripts	encoding	secreted	factors	or	myelin	sheath	proteins,	which	would	be	difficult	to	relate	to	a	cell	body.		Flow	cytometry	has	been	applied	to	dissected	lesion	tissue	with	some	success	in	the	cuprizone	model,	although	as	the	effected	regions	are	relatively	small	this	requires	pooling	of	large	numbers	of	mice	[62].	In	the	lysolecithin	model,	inflammatory	cells	from	the	lesion	and	normal	tissue	have	proved	difficult	to	separate	by	flow	cytometry,	probably	due	to	the	small	volume	of	affected	tissue	[80]	relative	to	the	more	global	inflammation	which	makes	this	possible	in	EAE	[81].	In	contrast	to	live	cells,	RNA	and	protein	from	a	small	region	of	CNS	containing	a	lysolecithin	lesion	have	been	reliably	used	to	investigate	remyelination	[82,	83].	Total	RNA	has	been	successfully	extracted	from	EB	lesions	very	selectively	using	laser	capture	microdissection	of	frozen	sections	[35],	revealing	general	patterns	in	gene	expression	at	different	timepoints	during	
remyelination.		
4.3 Conclusions Toxin-based	models	can	offer	a	valuable	insight	into	the	mechanisms	of	myelin	diseases,	and	into	broader	aspects	of	regenerative	medicine	[84].	Predictable	kinetics	and	a	temporal	dissociation	between	demyelination	and	remyelination	are	advantages	of	these	paradigms	that	complement	the	findings	of	other	model	systems.		
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Figures 
Figure	1:	Schematic	overview	of	the	mechanisms	by	which	lysolecithin	(a),	ethidium	bromide	(b)	and	cuprizone	(c)	cause	demyelination.		
	
	 	
Figure	2:	T2*-weighted	gadolinium-enhanced	Magnetic	Resonance	Image	(MRI)	of	brain	hemispheres	from	a	mouse	fed	a	0.2%	cuprizone	diet	for	5	weeks	(right)	and	a	control	animal	(left).	Myelin	appears	dark.	The	cuprizone-treated	mouse	shows	marked	demyelination	in	the	corpus	callosum	(white	boxes),	seen	here	at	its	caudal	end.		
	
	
	
	
Figure	3:	Injection	of	lysolecithin	into	the	ventral	white	matter	of	the	spinal	cord.	
	
	 	
Figure	4:	The	dorsal	surface	of	the	rat	skull.	The	lamba,	λ,	is	defined	as	the	midpoint	of	the	curve	of	best	fit	along	the	lambdoid	suture,	rather	than	the	intersection	between	the	lambdoid	and	sagittal	sutures.	
	
	
	
Figure	5:	Electron	micrographs	of	unlesioned	white	matter,	demyelination	and	remyelination,	highlighting	the	thinner	appearance	of	the	remyelinated	sheaths
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